- Breaking News LEAD: N. Korea calls for end to hostile relations with U.S
- Breaking News H.K. people march for democracy, release of Chinese dissident
- Breaking News N. Korea urges pro-Pyongyang body in Japan to help improve ties
- Breaking News 2ND LD: Death toll from suicide attack in Pakistan rises to 95
Cooper Industries reports fourth quarter earnings of $1.10 per share; Full-year 2005 earnings per share increases 15 percent to $4.12.
0 Comments | M2 Presswire, January, 2006
M2 PRESSWIRE-24 January 2006-Cooper Industries Ltd: Cooper Industries reports fourth quarter earnings of $1.10 per share; Full-year 2005 earnings per share increases 15 percent to $4.12(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:24012006 HOUSTON - Cooper Industries, Ltd. (NYSE: CBE) today reported fourth quarter 2005 earnings per share of $1.10 (diluted), an increase of 17 percent compared with $.94 earnings per share for the fourth quarter of 2004.
Fourth quarter 2005 revenues increased 3 percent to $1.19 billion, compared with $1.15 billion for the same period last year. For the fourth quarter of 2005, net income rose 17 percent to $104.0 million, compared with $88.9 million for the prior year's fourth quarter. The fourth quarter of 2005 included...
- Getting to the root of beautiful hair: shiny, silky hair begins with a healthy scalp - includes list of resources and a recipe for an herbal scalp tonic
- Industry Experts Launch Money Management Resources to Help People Overcome Debt and Learn Proper Money Management Practices
- Made from scratch: When Honda built a plant in Alabama it also built a workforce-using local workers who had no experience in making cars - Recruitment & Hiring
- Portfolio forecasting tools: what you need to know
- Banking technology, technological learning and competition: comparative case studies in Thai banking
- John Seely Brown Inducted Into 2004 Industry Hall of Fame
- SmartDisk's New VST Flash Media Reader(TM) Reads SmartMedia(TM), CompactFlash(TM) From A Single Desktop Unit
- FDA Approves REMICADE(R) for Ninth Indication: Psoriatic Arthritis